Compare Chipotle Mexican Grill, Inc. (CMG) vs Enveric Biosciences Inc (ENVB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Chipotle Mexican Grill, Inc. vs Enveric Biosciences Inc — how do they compare? Chipotle Mexican Grill, Inc. trades at $32.23 (market cap $40.67B), while Enveric Biosciences Inc trades at $1.45 (market cap $6.20M). The key difference: Chipotle Mexican Grill, Inc. is far larger — about 6559.7× Enveric Biosciences Inc's market cap, and Chipotle Mexican Grill, Inc. is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| CMG | ENVB | |
|---|---|---|
Market Cap | $40.67B | $6.20M |
Sector | Consumer Cyclical | Health |
52-Week High | $44.04 | $17.40 |
52-Week Low | $28.17 | $1.27 |
Enterprise Value | $45.42B | $1.30M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Chipotle Mexican Grill (CMG) trades at $32.81, down 2.67% amid food safety concerns. The stock shows bearish technical signals with strong analyst support (70% buy ratings) and a $42.17 consensus target. Recent quarterly earnings consistently beat expectations, with Q2 2026 EPS of $0.33 exceeding estimates. Revenue growth remains steady, climbing from $8.6B in 2022 to $11.9B in 2025, though net income margin compressed to 11.42% in 2026 from 13.55% in 2024.
Despite strong fundamentals and analyst optimism, CMG faces near-term headwinds from salmonella outbreaks and fraud investigations. The stock's premium valuation (P/E 29.76) requires sustained execution amid operational challenges. Long-term growth trajectory remains intact, but current sentiment is cautious due to food safety issues and legal scrutiny.
ENVB trades at $1.55, down 0.64% with a bullish technical signal despite negative profitability. The company shows promising clinical progress with its lead candidate EB-003, supported by recent FDA guidance and positive preclinical data. While quarterly earnings consistently beat expectations, the company remains unprofitable with negative ROE and ROA. Analyst sentiment is positive with 75% buy ratings.
Investment outlook hinges on successful drug development milestones, with regulatory progress and intellectual property expansion providing catalysts. Key risks include clinical trial outcomes, cash burn from operations, and dependence on financing activities. The stock presents speculative growth potential for risk-tolerant investors focused on biotech innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Chipotle Mexican Grill, Inc.
Chipotle Mexican Grill is the largest fast-casual chain restaurant in the United States, with systemwide sales of $7.5 billion in 2021. The Mexican concept is entirely company-owned, with a footprint of more than 3,000 stores, heavily indexed to the United States (though the firm maintains a small presence in Canada, the U.K., France, and Germany). Chipotle sells burritos, burrito bowls, tacos, quesadillas, and beverages, with a selling proposition built around competitive prices, high-quality food sourcing, speed of service, and convenience. The company generates its revenue entirely from restaurant sales and delivery fees.
Read more on CMG →About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →
